HEALTH ALERT!  For the safety of our patients and staff, effective March 30, 2020, new patients and patients with disabilities will be permitted one visitor over the age of 15. No other visitors will be permitted into the clinic.  Family members and caretakers may participate in the appointments remotely by phone or video conference if desired. Compass is working with other health care providers in the area to help contain the spread of the novel Coronavirus. We are taking active steps to minimize your exposure to the virus. These steps include screening everyone who enters the clinic for signs of illness, banning most visitors in the clinic, minimizing our own staffing and allowing some employees to work from home, and frequent sanitation of the clinic. We are using personal protective equipment such as masks, gowns, gloves, and face-shields according to national guidelines. We are working to identify those patients whose visits or treatments can be safely delayed, and we will notify you of this if you have an upcoming visit.  We ask that you stay home if you have fever and/or cough.

More Info

Clinical Trials

New Open Clinical Trial: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) NCT02889978

For more information call any Compass location and ask for the clinical research coordinator.


Cancer group:

  • New diagnosis of histologically confirmed cancer present in the patient (any stage IIV, as well as carcinoma in situ (CIS)), across multiple tumor types (see Appendix A) with no prior systemic cancer therapy and scheduled for surgical resection or nonsurgical management
  • Or, Subjects with a high suspicion for cancer diagnosis by clinical and radiological assessment, but without preceding histologic diagnosis, are eligible, if they have not received prior systemic cancer therapy and are scheduled for surgery
  • Has or will have a medically obtained pathological tumor specimen from core needle or surgical biopsy or removal of a metastatic mass or node within 90 days prior to study blood draw and/or planned surgical resection within 4 weeks (28 days) after study blood draw and pre-treatment

Non-Cancer group:

  • At least one guideline recommended cancer screening test documented in the medical record and performed within the timeframe indicated for age and gender as described in Appendix B; (eg, pap smear, mammography, and/or colonoscopy)
  • Prior diagnosis of cancer except: non-melanomatous skin cancer
  • Pregnancy (by self-report of pregnancy status)
  • Current febrile illness or active inflammatory disease
  • Poor health status or unfit to tolerate blood draw, as determined by the investigator


The study test(s) to be used in this protocol are next generation sequencing (NGS)-based assay(s) that are under development and investigation by the sponsor. Nucleic acids (NAs) isolated from biospecimens collected and stored in this protocol (blood components and tumor tissue) will be sequenced and analyzed. Blood components include, but are not limited to, cell-free nucleic acids (cfNAs) from plasma and NAs isolated from platelets, white blood cells, and exosomes. NGS of formalin-fixed, paraffin embedded (FFPE) tumor specimens.